A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer.
Richard S. Finn
Consultant or Advisory Role - Array BioPharma
Research Funding - Array BioPharma
Milind M. Javle
No relevant relationships to disclose
Benjamin R. Tan
Research Funding - Array BioPharma
Colin D. Weekes
No relevant relationships to disclose
Johanna C. Bendell
No relevant relationships to disclose
Amita Patnaik
Research Funding - Array BioPharma
Gazala Naaz Khan
No relevant relationships to disclose
Dan Laheru
No relevant relationships to disclose
Lisa Anderson
Employment or Leadership Position - Array BioPharma
Stock Ownership - Array BioPharma
Janna Lynn Christy-Bittel
Employment or Leadership Position - Array BioPharma
Stock Ownership - Array BioPharma
Emma Barrett
Employment or Leadership Position - Array BioPharma
Stock Ownership - Array BioPharma
Kari Guthrie
Employment or Leadership Position - Array BioPharma
Stock Ownership - Array BioPharma
Kevin S. Litwiler
Employment or Leadership Position - Array BioPharma
Stock Ownership - Array BioPharma
Tanios S. Bekaii-Saab
Consultant or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Genentech
Honoraria - Amgen; Genentech
Research Funding - Oncolytics Biotech; Pfizer